UNIVERSITY OF SYDNEY

Medidata has expanded its six-year partnership with the NHMRC Clinical Trials Centre at the University of Sydney, now supporting 30 concurrent studies through its unified platform.

Australian researchers have created PROTEUS, a groundbreaking "biological AI" platform that enables rapid evolution of molecules with new or enhanced functions directly inside mammalian cells.

Aethlon Medical successfully treated a second patient with its investigational Hemopurifier device in an Australian clinical trial targeting solid tumors resistant to anti-PD-1 therapies.

A groundbreaking 17-year international clinical trial involving 889 colon cancer patients shows that structured exercise programs reduce cancer recurrence risk by 28% and death risk by 37%.

The National Health and Medical Research Council (NHMRC) has awarded $8.3 million to University of Sydney researchers for clinical trials addressing critical gaps in cancer and addiction treatment.

Westmead Hospital launches groundbreaking clinical trials for Fosmanogepix, a new class of antifungal drug designed to combat drug-resistant invasive fungal infections.

• Phase 3 INTEGRATE IIa trial demonstrates regorafenib extends median overall survival to 4.5 months versus 4.0 months with placebo in refractory advanced gastric/GEJ cancer patients. • Treatment with regorafenib significantly delayed disease progression and quality-of-life deterioration, with a progression-free survival of 1.8 months compared to 1.6 months for placebo. • The study validates regorafenib's potential as a treatment platform, supporting its investigation in combination therapies including ongoing trials with nivolumab and chemotherapy.

A new review indicates limited evidence supports the use of antidepressants for pain relief in older adults, raising concerns about potential overuse.

Professor Richard Scolyer, diagnosed with terminal stage 4 glioblastoma in 2023, remains cancer-free one year after receiving a first-of-its-kind immunotherapy treatment he helped develop.